Gilead's third acquisition of 2026 is the purchase of German startup Tubulis for $3.15 billion upfront1
The deal targets Tubulis' next-generation antibody-drug conjugate (ADC) platform1
Gilead could pay an additional $1.85 billion in potential milestone payments1
Tubulis raised $401 million in a Series C funding round last year3
Sources:
1. https://helixgatebiotechreview.com/gilead-continues-dealmaking-streak-with-3-15b-tubulis-buy-for-adcs/?amp=1
3. https://synapse.patsnap.com/organization/8d22e0039bbdb7273241eaeab92ae132